CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup

Angela Bowman, Hani Gabra, Simon P Langdon, Alastair Lessells, Moira Stewart, Ann Young, John F Smyth

Research output: Contribution to journalArticlepeer-review

Abstract

This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response.
Original languageEnglish
Pages (from-to)2233-9
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number7
Publication statusPublished - Jul 2002

Keywords

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • CA-125 Antigen
  • Disease Progression
  • Enzyme Inhibitors
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Middle Aged
  • Nitriles
  • Ovarian Neoplasms
  • Receptor, Epidermal Growth Factor
  • Receptor, erbB-2
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Triazoles

Fingerprint

Dive into the research topics of 'CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup'. Together they form a unique fingerprint.

Cite this